Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Update

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 31,100 shares, an increase of 168.1% from the October 15th total of 11,600 shares. Based on an average daily trading volume, of 366,500 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.8% of the company’s shares are sold short.

Altamira Therapeutics Stock Up 3.7 %

NASDAQ CYTO traded up $0.02 during trading hours on Thursday, reaching $0.43. The company’s stock had a trading volume of 993,966 shares, compared to its average volume of 751,378. The firm has a fifty day simple moving average of $0.63 and a 200-day simple moving average of $1.04. Altamira Therapeutics has a 52 week low of $0.40 and a 52 week high of $17.20.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.